SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXY is drawing attention as it pushes through technical resistance alongside strength in oil stocks, with traders also pointing to call-heavy options activity and the companys debt reduction and cash-flow outlook. The debate centers on whether support from elevated oil and supply risks can persist or whether a possible Iran deal and falling crude prices would weigh on the shares.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of the Q3 report is drawing attention, with traders citing BRIUMVIs commercial growth and possible guidance upside. Buyout and short-squeeze speculation is prominent, though others view the move as momentum into earnings rather than evidence of a deal.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Attention is focused on Affirms upcoming quarterly report, with traders weighing a slower growth outlook against signs of continued demand and analyst optimism. Others are cautious about consumer-credit and macroeconomic risks, contributing to mixed sentiment ahead of the results.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

XLV is drawing attention as traders describe a rotation into defensive healthcare amid weakness in technology, citing the sectors outperformance, breakout and strength across healthcare holdings. Some are buying or holding the advance, while others see the move as extended and are considering trimming.

Vermilion Energy, Inc. engages in the acquisition, exploration, development, and production of oil and natural gas. It operates through the following geographical segments: Canada, United States of America, France, Netherlands, Germany, Ireland, Australia, and Corporate. The company was founded by Lorenzo Donadeo and Claudio A. Ghersinich in 1994 and is headquartered in Calgary, Canada.

Vermilion Energy Inc

Traders are focused on the Iran-related disruption risk to Gulf energy supplies and rising European natural-gas prices, viewing Vermilions European production as potential leverage to a tighter market. The discussion is largely bullish, but some caution that gains could reverse if tensions ease and point to possible European windfall taxes.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of a competing RRP treatment has put pressure on Precigens PAPZIMEOS story and raised questions about future market share. Traders are divided: some see a threat from the rivals treatment approach, while others point to Precigens first-mover position, full approval, and established commercial launch as advantages.

Hyperliquid (HYPE) is a cryptocurrency and operates on the Hyperliquid platform. Hyperliquid has a current supply of 950,404,567.00039228 with 253,519,445.96520927 in circulation. The last known price of Hyperliquid is 87.80548337 USD and is down -2.36 over the last 24 hours. It is currently trading on 350 active market(s) with $1,945,115,780.75 traded over the last 24 hours. More information can be found at https://hyperliquid.xyz/.

Hype

HYPEs strong rally and push toward record levels have traders debating whether it can break through key resistance, with bullish posts pointing to fee-funded buybacks and Hyperliquids expanding role in on-chain and regulated derivatives markets. Others caution that the token remains volatile and could pull back.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is drawing attention as traders react to its sharp move amid Nasdaq volatility, with speculation about a possible Iran deal and Strait of Hormuz reopening fueling debate over whether markets will rally or face further pressure. Some traders expect a rebound and caution against bearish positions, while others continue to use the inverse ETF as a hedge amid concerns about tech valuations and AI spending.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,348.93. The last known price of BNB is 702.2705794 USD and is down -0.19 over the last 24 hours. It is currently trading on 3523 active market(s) with $1,103,086,320.06 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Binances reported multibillion-dollar security breach and temporary withdrawal disruption dominate discussion, with traders voicing fears about exchange solvency, customer-fund safety and withdrawals while questioning the breachs cause. Others argue Binance can cover losses and view the limited token selloff as a sign of resilience.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Positive Phase 3 data for Amgens IMDELLTRAImfinzi combination in extensive-stage small-cell lung cancer is supporting attention, alongside the upcoming quarterly report as shares trade near recent highs. Traders are debating whether put-heavy options activity reflects earnings hedging or bearish positioning; call buying points to interest on both sides.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million.
Tvardi Therapeutics (NASDAQ:TVRD)read more...

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion.
Tvardi Therapeutics (NASDAQ:TVRD)read more...

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors...

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. (Tvardi or the Company) (NASDAQ: TVRD). This press release features...

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf...

Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Tvardi (TVRD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat...

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc.. (Tvardi or the Company) (NASDAQ: TVRD). Faruqi & Faruqi is a leading...

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX.

Tvardi Therapeutics Inc.

Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?

Equity

Bullish Sentiment

Tvardi Therapeutics (TVRD) on Monday said that its TTI-101, being evaluated in idiopathic pulmonary fibrosis (IPF), showed no benefit over placebo in a mid-stage trial.The trial was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function in patients with IPF. Idiopathic Pulmonary Fibrosis is a progressive lung disease where lung tissue thickens and scars, making it difficult to breathe. However, the study did not meet its goals, and no statistically significant differences between placebo and treatment arms were observed after a preliminary review of exploratory efficacy, it said.Shares of the company plummeted 87% in Monday’s pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TVRD">TVRD stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.Tvardi said that preliminary data showed that patients’ baseline characteristics were mostly similar across treatment arms, including those who received the two doses of TTI-101 or those who received a placebo in the trial. Furthermore, lower discontinuation rates were observed in the placebo group compared to the therapy-treated arms, it added.The company also noted that patients who demonstrated changes in the lung’s Forced Vital Capacity (FVC) were 41% for the placebo, and 39% and 44% for the 400mg and 800mg TTI-101-treated arms, respectively.“In the aggregate, we did not observe a benefit of TTI-101 treatment in this IPF study. The limited data set, high variability within treatment arms, and unexpected performance of the placebo arm make it difficult to provide more definitive conclusions at this time,” CEO Imran Alibhai said.The CEO added that the company is now conducting additional analyses to understand the trial findings further. He also noted that the company is on track to report preliminary data from the mid-stage trial of TTI-101 in hepatocellular carcinoma.TVRD stock has risen about 127% this year and more than quadrupled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-commences-production-ramp-up-at-shanghai-gigafactory/ch6SiqpR3kW">Tesla Reportedly Commences Production Ramp-Up At Its Shanghai Gigafactory</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review of exploratory efficacy. 

iShares Russell 2000 Growth ETF

Tvardi Therapeutics, Inc.

ProShares Ultra Russell2000

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.7928
Prev Close	$0.863
Open	$0.8677
Dividend Yield	0.00%
50-Day Moving Average	$1.38
Beta	-0.32
Avg. Volume	209,381.20
PE Ratio	-0.29

52-Week High	$5.69
52-Week Low	$0.7729
Market Capitalization	$10.58M
EPS (Annual)	-$3.26
Price to Book	0.89
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TVRD Fundamentals